Mechanisms of augmented UVB immunosuppressive responses by polyaromatic hydrocarbons

多环芳烃增强 UVB 免疫抑制反应的机制

基本信息

  • 批准号:
    10688121
  • 负责人:
  • 金额:
    $ 18.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Abstract Humans are subjected daily to multiple and often simultaneous environmental stressors. Yet the complex interaction of these agents remains an understudied area. Notably, ultraviolet radiation (UVR) has profound effects on the skin and generates systemic consequences from fever to immunosuppression to vitamin D production. The ability of UVR to act as both immunosuppressant and mutagen allows this environmental agent to become a complete carcinogen and is the cause for non-melanoma skin cancer and melanoma. Besides, environmental pollutants, polycyclic aromatic hydrocarbons (PAH) are ubiquitous and exert immunomodulatory as well as pro-carcinogenic effects, in great part via acting as agonists for the aryl hydrocarbon receptor (AHR). However, there is a significant knowledge gap of interactions between UVR and pollutants. In particular, as UVB only penetrates the epidermis, a major question in photobiology is how UVB-treated skin sends systemic signals. Recent studies have indicated that small membrane-bound vesicles known as microvesicle particles (MVP) released from cells in response to various stressors can act as potent signaling agents due to their ability to carry nuclear and cytoplasmic components. We have demonstrated that UVB (not UVA) generates MVP release from epithelial cells and skin, which could provide a potential mechanism for UVB-mediated systemic signaling. Our group and others have shown that UVB (not UVA) generates high levels of the lipid mediator Platelet-activating factor (PAF) produced enzymatically and oxidized PAF agonists produced non-enzymatically via reactive oxygen species (ROS). Recent studies using PAFR-expressing/null cell lines and pharmacologic/genetic inhibition of ROS, and the enzyme acid sphingomyelinase (aSMase) have implicated the involvement of the PAF-receptor (PAFR) signaling resulting in aSMase activation in UVB generated MVP (UVB-MVP). We provide evidence that UVB-MVP carry bioactive PAF agonists, which we hypothesize mediate the delayed immunosuppressive effects of UVB. Importantly, we discovered that the PAH Benzo[a]pyrene (BaP) interaction with UVB releases high levels of UVB-MVP and generate increased levels of PAF agonists. Two aims are planned to test the hypothesis that BaP+UVR (UVA vs UVB) results in a synergistic production of ROS that generate PAF and UVR-MVP resulting in enhanced systemic immunosuppression in an AHR-independent manner. Aim 1 will use in vitro cell lines, ex vivo skin explants and in vivo murine genetic and pharmacologic models to determine the mechanisms of BaP augmentation of UVB-MVP and PAF generation as well as define PAFR role in BaP synergy with UVR using a simulated solar light (SSL) source that emits both UVA and UVB fluences. Aim 2 will define the roles of enhanced UVB-MVP generation by BaP and the involvement of Tregs and cytokines, including IL-10 and TGFβ in delayed immunosuppressive effects. Successful completion of this project will (i) define a novel mechanism by which a PAH pollutant can augment UVR-induced effects; and ii) address an important question in photobiology as to how a keratinocyte-specific stimulus can generate systemic signaling effects.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ravi PRAKASH Sahu其他文献

Ravi PRAKASH Sahu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ravi PRAKASH Sahu', 18)}}的其他基金

Oxidized lipids and microvesicle particles as effectors for chemical threats to skin
氧化脂质和微泡颗粒作为皮肤化学威胁的效应器
  • 批准号:
    10648739
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
Mechanisms of augmented UVB immunosuppressive responses by polyaromatic hydrocarbons
多环芳烃增强 UVB 免疫抑制反应的机制
  • 批准号:
    10527648
  • 财政年份:
    2022
  • 资助金额:
    $ 18.75万
  • 项目类别:
Environmental pro-oxidative stressors and immunosuppression
环境促氧化应激源和免疫抑制
  • 批准号:
    9130895
  • 财政年份:
    2014
  • 资助金额:
    $ 18.75万
  • 项目类别:
Environmental pro-oxidative stressors and immunosuppression
环境促氧化应激源和免疫抑制
  • 批准号:
    8679252
  • 财政年份:
    2014
  • 资助金额:
    $ 18.75万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 18.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 18.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 18.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了